

Figures 1A - 1B

FPF=95%

MMAD=2.8 μ m




Figure 2




Figure 3










Figure 4



Figures 5A - 5B



Figures 6A - 6B



Figures 7A - 7D




Figure 8









Figure 9



Figures 10A - 10B



Figures 11A - 11C






Figure 12

A. Activation of TcH by HA 110-120 integrated in Ig, in context of B lymphoma APC




B. *In vitro* stimulation of TcH by IgHA in context of B lymphoma APC (18 hours incubation)




Figures 13A - 13B


A. InsB / α -CD3 stimulated splenocytes






B. GAD/ anti-CD3 stimulated splenocytes





C. Peptide-stimulated splenocytes



Figures 14A - 14C



Figures 15A - 15C



Figures 16A - 16B






Figure 17




A. Th profile in MALT



B. Th profile in spleen




Figures 18A - 18B




Figures 19A - 19C



A. Kinetics of disease (adm. 8-10w)





B. Kinetics of disease (8-20w)




Figures 20A - 20B



Figures 21A - 21B



Figures 22A - 22B



Figures 23A - 23B




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31